C1 Esterase Inhibitor Reduces Lower Extremity Ischemia/Reperfusion Injury and Associated Lung Damage

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Duehrkop, Claudia ^a   Banz, Yara ^a   Spirig, Rolf ^b   Miescher, Sylvia ^b   Nolte, Marc W ^c   Spycher, Martin ^b   Smith, Richard A G ^d   Sacks, Steven H ^d   Rieben, Robert ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b CSL Behring AG   (Switzerland)

^c CSL BEHRING GMBH   (Germany)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ B1 RECEPTOR; COMPLEMENT; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3C; CXCL1 CHEMOKINE; FIBRIN; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MIROCOCEPT; MYELOPEROXIDASE; RANTES; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMORAL ARTERY; FIBRIN DEPOSITION; GASTROCNEMIUS MUSCLE; HINDLIMB; HISTOLOGY; IMMUNOFLUORESCENCE; LEG INJURY; LIMB ISCHEMIA; LUNG INJURY; LUNG PARENCHYMA; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; REPERFUSION INJURY; TOURNIQUET; UPREGULATION; WISTAR RAT;

ANIMALS; ANTIGENS, CD; APOPTOSIS; CADHERINS; CHEMOKINES; COMPLEMENT C1 INHIBITOR PROTEIN; CYTOKINES; EDEMA; FIBRIN; HINDLIMB; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLAMMATION MEDIATORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG; MICROSCOPY, FLUORESCENCE; MUSCLES; RATS; RATS, WISTAR; RECEPTOR, BRADYKININ B1; REPERFUSION INJURY;

EID: 84883074947     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072059     Document Type: Article

References (59)

1. Zhang M, Alicot EM, Chiu I, Li J, Verna N, et al. (2006) Identification of the target self-antigens in reperfusion injury. J Exp Med 203: 141-152.
2. Kulik L, Fleming SD, Moratz C, Reuter JW, Novikov A, et al. (2009) Pathogenic natural antibodies recognizing annexin IV are required to develop intestinal ischemia-reperfusion injury. J Immunol 182: 5363-5373.
3. Cooper NR, (1985) The classical complement pathway: activation and regulation of the first complement component. Adv Immunol 37: 151-216.
4. McMullen ME, Hart ML, Walsh MC, Buras J, Takahashi K, et al. (2006) Mannose-binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo. Immunobiology 211: 759-766.
5. Weiser MR, Williams JP, Moore FD Jr, Kobzik L, Ma M, et al. (1996) Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med 183: 2343-2348.
6. Schoots IG, Levi M, van Vliet AK, Maas AM, Roossink EH, et al. (2004) Inhibition of coagulation and inflammation by activated protein C or antithrombin reduces intestinal ischemia/reperfusion injury in rats. Crit Care Med 32: 1375-1383.
7. Okada Y, Copeland BR, Fitridge R, Koziol JA, del Zoppo GJ, (1994) Fibrin contributes to microvascular obstructions and parenchymal changes during early focal cerebral ischemia and reperfusion. Stroke 25: 1847-1854.
8. Edagawa M, Yoshida E, Matsuzaki Y, Shibuya K, Shibata K, et al. (1999) Reduction of post-ischemic lung reperfusion injury by fibrinolytic activity suppression. Transplantation 67: 944-949.
9. Chong AJ, Pohlman TH, Hampton CR, Shimamoto A, Mackman N, et al. (2003) Tissue factor and thrombin mediate myocardial ischemia-reperfusion injury. Ann Thorac Surg 75: S649-655.
10. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, et al. (2006) Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 12: 682-687.
11. Gouverneur M, Berg B, Nieuwdorp M, Stroes E, Vink H, (2006) Vasculoprotective properties of the endothelial glycocalyx: effects of fluid shear stress. J Intern Med 259: 393-400.
12. Mulivor AW, Lipowsky HH, (2004) Inflammation- and ischemia-induced shedding of venular glycocalyx. Am J Physiol Heart Circ Physiol 286: H1672-1680.
13. Rehm M, Bruegger D, Christ F, Conzen P, Thiel M, et al. (2007) Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation 116: 1896-1906.
14. Mulivor AW, Lipowsky HH, (2002) Role of glycocalyx in leukocyte-endothelial cell adhesion. Am J Physiol Heart Circ Physiol 283: H1282-1291.
15. Yassin MM, Harkin DW, Barros D'Sa AA, Halliday MI, Rowlands BJ, (2002) Lower limb ischemia-reperfusion injury triggers a systemic inflammatory response and multiple organ dysfunction. World J Surg 26: 115-121.
16. Punch J, Rees R, Cashmer B, Oldham K, Wilkins E, et al. (1991) Acute lung injury following reperfusion after ischemia in the hind limbs of rats. J Trauma 31: 760-765; discussion 765-767.
17. Seekamp A, Warren JS, Remick DG, Till GO, Ward PA, (1993) Requirements for tumor necrosis factor-alpha and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury. Am J Pathol 143: 453-463.
18. Smith RA, (2002) Targeting anticomplement agents. Biochem Soc Trans 30: 1037-1041.
19. Smith GP, Smith RA, (2001) Membrane-targeted complement inhibitors. Mol Immunol 38: 249-255.
20. Banz Y, Hess OM, Robson SC, Csizmadia E, Mettler D, et al. (2007) Attenuation of myocardial reperfusion injury in pigs by Mirococept, a membrane-targeted complement inhibitor derived from human CR1. Cardiovasc Res 76: 482-493.
21. Zeerleder S, (2011) C1-inhibitor: more than a serine protease inhibitor. Semin Thromb Hemost 37: 362-374.
22. Landerman NS, Webster ME, Becker EL, Ratcliffe HE, (1962) Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy 33: 330-341.
23. Bork K, Meng G, Staubach P, Hardt J, (2006) Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 119: 267-274.
24. Horstick G, Heimann A, Gotze O, Hafner G, Berg O, et al. (1997) Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation 95: 701-708.
25. De Simoni MG, Storini C, Barba M, Catapano L, Arabia AM, et al. (2003) Neuroprotection by complement (C1) inhibitor in mouse transient brain ischemia. J Cereb Blood Flow Metab 23: 232-239.
26. Heijnen BH, Straatsburg IH, Padilla ND, Van Mierlo GJ, Hack CE, et al. (2006) Inhibition of classical complement activation attenuates liver ischaemia and reperfusion injury in a rat model. Clin Exp Immunol 143: 15-23.
27. Nielsen EW, Mollnes TE, Harlan JM, Winn RK, (2002) C1-inhibitor reduces the ischaemia-reperfusion injury of skeletal muscles in mice after aortic cross-clamping. Scand J Immunol 56: 588-592.
28. Swiss Academy of Medical S, Swiss Academy of S, (1997) Ethical principles and guidelines for scientific experiments on animals. Altern Lab Anim 25: 379-384.
29. Dick F, Li J, Giraud MN, Kalka C, Schmidli J, et al. (2008) Basic control of reperfusion effectively protects against reperfusion injury in a realistic rodent model of acute limb ischemia. Circulation 118: 1920-1928.
30. Kunschak M, Engl W, Maritsch F, Rosen FS, Eder G, et al. (1998) A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 38: 540-549.
31. Bianchi C, Araujo EG, Sato K, Sellke FW, (2001) Biochemical and structural evidence for pig myocardium adherens junction disruption by cardiopulmonary bypass. Circulation 104: I319-324.
32. Kao MC, Jan WC, Tsai PS, Wang TY, Huang CJ, (2011) Magnesium sulfate mitigates lung injury induced by bilateral lower limb ischemia-reperfusion in rats. J Surg Res 171: e97-106.
33. Austinat M, Braeuninger S, Pesquero JB, Brede M, Bader M, et al. (2009) Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema. Stroke 40: 285-293.
34. Toomayan GA, Chen LE, Jiang HX, Qi WN, Seaber AV, et al. (2003) C1-esterase inhibitor and a novel peptide inhibitor improve contractile function in reperfused skeletal muscle. Microsurgery 23: 561-567.
35. Souza DG, Esser D, Bradford R, Vieira AT, Teixeira MM, (2005) APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br J Pharmacol 145: 1027-1034.
36. Pedersen ED, Waje-Andreassen U, Vedeler CA, Aamodt G, Mollnes TE, (2004) Systemic complement activation following human acute ischaemic stroke. Clin Exp Immunol 137: 117-122.
37. Heydenreich N, Nolte MW, Gob E, Langhauser F, Hofmeister M, et al. (2012) C1-Inhibitor Protects From Brain Ischemia-Reperfusion Injury by Combined Antiinflammatory and Antithrombotic Mechanisms. Stroke 43: 2457-2467.
38. Colman RW, (1969) Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun 35: 273-279.
39. Goldsmith GH Jr, Saito H, Ratnoff OS, (1978) The activation of plasminogen by Hageman factor (Factor XII) and Hageman factor fragments. J Clin Invest 62: 54-60.
40. Ravindran S, Grys TE, Welch RA, Schapira M, Patston PA, (2004) Inhibition of plasma kallikrein by C1-inhibitor: role of endothelial cells and the amino-terminal domain of C1-inhibitor. Thromb Haemost 92: 1277-1283.
41. Brown EW, Ravindran S, Patston PA, (2002) The reaction between plasmin and C1-inhibitor results in plasmin inhibition by the serpin mechanism. Blood Coagulation & Fibrinolysis 13: 711-714.
42. Kemp M, Donovan J, Higham H, Hooper J, (2004) Biochemical markers of myocardial injury. Br J Anaesth 93: 63-73.
43. Witherow FN, Helmy A, Webb DJ, Fox KA, Newby DE, (2001) Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation 104: 2177-2181.
44. Hashimoto N, Takeyoshi I, Tsutsumi H, Sunose Y, Tokumine M, et al. (2004) Effects of a bradykinin B(2) receptor antagonist on ischemia-reperfusion injury in a canine lung transplantation model. J Heart Lung Transplant 23: 606-613.
45. Souza DG, Lomez ES, Pinho V, Pesquero JB, Bader M, et al. (2004) Role of bradykinin B2 and B1 receptors in the local, remote, and systemic inflammatory responses that follow intestinal ischemia and reperfusion injury. J Immunol 172: 2542-2548.
46. Stallone RJ, Lim RC Jr, Blaisdell FW, (1969) Pathogenesis of the pulmonary changes following ischemia of the lower extremities. Ann Thorac Surg 7: 539-549.
47. Grommes J, Soehnlein O, (2011) Contribution of neutrophils to acute lung injury. Mol Med 17: 293-307.
48. Gadaleta D, Fantini GA, Silane MF, Davis JM, (1994) Leukotriene generation and pulmonary dysfunction following aortic cross clamp in humans. Ann N Y Acad Sci 723: 470-472.
49. Bray MA, Cunningham FM, Ford-Hutchinson AW, Smith MJ, (1981) Leukotriene B4: a mediator of vascular permeability. Br J Pharmacol 72: 483-486.
50. Cai S, Davis AE, (2003) Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion. J Immunol 171: 4786-4791.
51. Cai S, Dole VS, Bergmeier W, Scafidi J, Feng H, et al. (2005) A direct role for C1 inhibitor in regulation of leukocyte adhesion. J Immunol 174: 6462-6466.
52. Li R, Ren M, Chen N, Luo M, Zhang Z, et al. (2012) Vitronectin increases vascular permeability by promoting VE-cadherin internalization at cell junctions. PLoS One 7: e37195.
53. Inderbitzin D, Beldi G, Avital I, Vinci G, Candinas D, (2004) Local and remote ischemia-reperfusion injury is mitigated in mice overexpressing human C1 inhibitor. Eur Surg Res 36: 142-147.
54. Eefting F, Rensing B, Wigman J, Pannekoek WJ, Liu WM, et al. (2004) Role of apoptosis in reperfusion injury. Cardiovasc Res 61: 414-426.
55. Fu J, Lin G, Wu Z, Ceng B, Wu Y, et al. (2006) Anti-apoptotic role for C1 inhibitor in ischemia/reperfusion-induced myocardial cell injury. Biochem Biophys Res Commun 349: 504-512.
56. Lu F, Fernandes SM, Davis AE, (2012) The effect of C1 inhibitor on myocardial ischemia and reperfusion injury. Cardiovasc Pathol.
57. Ege T, Us MH, Sungun M, Duran E, (2004) Cytokine response in lower extremity ischaemia/reperfusion. J Int Med Res 32: 124-131.
58. Liao YH, Xia N, Zhou SF, Tang TT, Yan XX, et al. (2012) Interleukin-17A contributes to myocardial ischemia/reperfusion injury by regulating cardiomyocyte apoptosis and neutrophil infiltration. J Am Coll Cardiol 59: 420-429.
59. Hsieh CH, Frink M, Hsieh YC, Kan WH, Hsu JT, et al. (2008) The role of MIP-1 alpha in the development of systemic inflammatory response and organ injury following trauma hemorrhage. J Immunol 181: 2806-2812.